Denali Therapeutics, Inc. (DNLI)
24.20
-0.72
(-2.89%)
USD |
NASDAQ |
Aug 24, 16:00
23.73
-0.47
(-1.94%)
After-Hours: 20:00
Denali Therapeutics EPS Diluted (Quarterly) : -0.681 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.681 |
| March 31, 2026 | -0.6882 |
| December 31, 2025 | -0.7326 |
| September 30, 2025 | -0.736 |
| June 30, 2025 | -0.7239 |
| March 31, 2025 | -0.7766 |
| December 31, 2024 | -0.6747 |
| September 30, 2024 | -0.6326 |
| June 30, 2024 | -0.5865 |
| March 31, 2024 | -0.6814 |
| December 31, 2023 | -0.8642 |
| September 30, 2023 | -0.7218 |
| June 30, 2023 | 1.301 |
| March 31, 2023 | -0.8041 |
| December 31, 2022 | -0.7426 |
| September 30, 2022 | -0.8366 |
| June 30, 2022 | -0.478 |
| March 31, 2022 | -0.5316 |
| December 31, 2021 | -0.6161 |
| September 30, 2021 | -0.6948 |
| Date | Value |
|---|---|
| June 30, 2021 | -0.5015 |
| March 31, 2021 | -0.5794 |
| December 31, 2020 | 1.909 |
| September 30, 2020 | -0.5417 |
| June 30, 2020 | -0.5585 |
| March 31, 2020 | -0.5542 |
| December 31, 2019 | -0.5623 |
| September 30, 2019 | -0.4826 |
| June 30, 2019 | -0.6109 |
| March 31, 2019 | -0.4105 |
| December 31, 2018 | 0.7932 |
| September 30, 2018 | -0.3776 |
| June 30, 2018 | -0.59 |
| March 31, 2018 | -0.2644 |
| December 31, 2017 | -0.74 |
| September 30, 2017 | -0.2425 |
| June 30, 2017 | -0.2458 |
| March 31, 2017 | 1.808 |
| December 31, 2016 | -0.2149 |
| September 30, 2016 | -0.3399 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Biogen, Inc. | 0.6557 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -127.55M |
| Revenue (Quarterly) | 3.604M |
| Total Expenses (Quarterly) | 131.16M |
| Enterprise Value | 3.308B |
| Gross Profit Margin (Quarterly) | -52.39% |
| Profit Margin (Quarterly) | -3.54K% |
| Earnings Yield | -11.73% |
| Normalized Earnings Yield | -11.73 |